Trial Profile

A Phase 1 Dose Escalation Study to Assess Safety and Efficacy of ADP-A2M4CD8 As Monotherapy or in Combination with Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects with MAGE-A4 Positive Tumors (SURPASS)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 17 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Uzatresgene autoleucel (Primary) ; Nivolumab; Pembrolizumab
Indications Adenocarcinoma; Bladder cancer; Carcinoma; Gastric cancer; Head and neck cancer; Malignant melanoma; Myxoid liposarcoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Synovial sarcoma; Urogenital cancer
Focus Adverse reactions; First in man
Acronyms SURPASS
Sponsors Adaptimmune

13 Mar 2025 Status changed from recruiting to active, no longer recruiting.
12 Aug 2024 According to an Adaptimmune media release, screening in the SURPASS Phase 1 trial has stopped and enrolment will cease shortly.
15 Feb 2024 Planned primary completion date changed from 30 Sep 2023 to 23 Dec 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com